SCHEMBL3013872

SCHEMBL3013872

COc1ccc(S(=O)(=O)N2CCN(c3nc(Cc4c(C)cc(C)cc4C)cs3)CC2)c(OC)c1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.47
ALDH1A1 P00352 4/20 0.47
RECQL P46063 2/20 0.47
PKM P14618 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAPK1 P28482 1/20 0.43
L3MBTL1 Q9Y468 4/20 0.43
KMT2A Q03164 2/20 0.43
USP2 O75604 2/20 0.42
HSD17B10 Q99714 2/20 0.42
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41
TP53 P04637 1/20 0.41
MCOLN3 Q8TDD5 1/20 0.41
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3651253 0.94 ALDH1A1 (0.42) MAPTALDH1A1RECQLPKMSMN1; SMN2
SCHEMBL3013337 0.93 ALDH1A1 (0.56) MAPTALDH1A1RECQLMAPK1L3MBTL1
SCHEMBL3011432 0.93 MAPT (0.54) MAPTALDH1A1RECQLPKMSMN1; SMN2
SCHEMBL3007417 0.90 MAPT (0.46) MAPTALDH1A1RECQLPKMSMN1; SMN2
SCHEMBL3648129 0.89 HTT (0.45) MAPTALDH1A1RECQLSMN1; SMN2MAPK1
SCHEMBL3016750 0.88 MAPK1 (0.46) MAPTALDH1A1RECQLPKMSMN1; SMN2
SCHEMBL3019573 0.88 MAPK1 (0.46) MAPTALDH1A1RECQLPKMSMN1; SMN2
SCHEMBL3013082 0.87 ALDH1A1 (0.46) MAPTALDH1A1RECQLPKMSMN1; SMN2
SCHEMBL3001778 0.87 MAPT (0.46) MAPTALDH1A1RECQLPKMSMN1; SMN2
SCHEMBL3647462 0.87 ALDH1A1 (0.50) MAPTALDH1A1RECQLMAPK1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885ALDH1A1 3510/4885RECQL 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.